We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Robot Assisted Prostate Cancer Surgery Shows Good Results

By HospiMedica International staff writers
Posted on 10 May 2012
A new study shows that robot-assisted surgery for the removal of cancerous prostate has outcomes as good, if not better, than open or laparoscopic radical prostatectomy (RP) techniques.

Researchers at New York-Presbyterian Hospital/Weill Cornell Medical Center (NYP; New York, NY, USA) and Karolinska University Hospital (Stockholm, Sweden) conducted a literature review and meta-analysis to compare margin and perioperative complication rates for open retropubic RP (ORP), laparoscopic RP (LRP), and robot-assisted LRP (RALP). More...
The data were abstracted from 400 original research articles published between 2002 and 2010, representing 167,184 ORP, 57,303 LRP, and 62,389 RALP patients (total 286,876). The primary outcomes were positive surgical margin (PSM) rates, as well as total intra- and peri-operative complication rates.

The results showed that the LRP group had higher positive surgical margin rates than the RALP group, but similar rates to the ORP group. LRP and RALP showed significantly lower blood loss and transfusions, and a shorter length of hospital stay than the ORP group. Total perioperative complication rates were higher for ORP and LRP than for RALP. Total intraoperative complication rates were low for all modalities, but lowest for RALP. Rates for readmission, reoperation, nerve, ureteral, and rectal injury, deep vein thrombosis (DVT), pneumonia, hematoma, lymphocele, anastomotic leak, fistula, and wound infection showed significant differences between groups, generally favoring RALP. The study was published early online on February 24, 2012, in European Urology.

“We would love to be able to directly compare the three prostatectomy surgical techniques, but that may not happen. This study is the first to provide an important, and much needed, analysis of the short term benefits and risks between curative surgeries that many men rely on,” said lead author, Ashutosh Tewari, MD, director of the Prostate Cancer Institute at NYP. “Since the robotic technology is expensive, the patient benefits often get intertwined with the societal costs. It is clear, however, that robotic surgery is the most popular surgical modality today.”

Related Links:

New York-Presbyterian Hospital/Weill Cornell Medical Center
Karolinska University Hospital



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ureteral Dilatation Balloon
Dornier Equinox
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.